| Phase 14 trials |
|
Phase 1
|
NCT05567159 |
Oct 2022 → Jul 2023 |
— |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05533411 |
Sep 2022 → Jan 2023 |
— |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02624778 |
Dec 2015 → Aug 2019 |
Alzheimer disease |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01837641 |
May 2013 → Aug 2016 |
Alzheimer disease |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT07167966 |
Nov 2026 → Aug 2028 expected |
Alzheimer disease |
Paul S. Aisen |
Enrolling by invitation
|
No outcome recorded
|
|
Phase 2
|
NCT07589595 |
May 2026 → Aug 2028 expected |
Lewy body dementia, amyloidosis |
Eli Lilly and Company |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04640077 |
Nov 2020 → Feb 2024 |
Alzheimer disease, brain disorder |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03367403 |
Dec 2017 → Dec 2020 |
Alzheimer disease |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT06996730 |
Jan 2026 → Jun 2030 expected |
early-onset autosomal dominant Alzheimer disease |
Banner Health |
Not yet recruiting
|
No outcome recorded
|
| Phase 37 trials |
|
Phase 3
|
NCT07602582 |
May 2026 → Sep 2029 expected |
Alzheimer disease, senile plaque formation |
Eli Lilly and Company |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07571161 |
Apr 2026 → Apr 2030 expected |
Alzheimer disease |
Eli Lilly and Company |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05738486 |
Feb 2023 → May 2024 overdue |
Alzheimer disease, mental disorder |
Eli Lilly and Company |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05508789 |
Oct 2022 → May 2028 expected |
Alzheimer disease, mental disorder |
Eli Lilly and Company |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05108922 |
Nov 2021 → Sep 2022 |
Alzheimer disease |
Eli Lilly and Company |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05026866 |
Aug 2021 → Nov 2027 expected |
Alzheimer disease |
Eli Lilly and Company |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04437511 |
Jun 2020 → Apr 2023 overdue |
Alzheimer disease |
Eli Lilly and Company |
Active not recruiting
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT06911944 |
Aug 2026 → Dec 2028 expected |
Alzheimer disease, trisomy 21 |
Michael Rafii, MD, PhD |
Not yet recruiting
|
No outcome recorded
|